ethyl 3-amino-2-phenylpropyl(diethoxymethyl)phosphinate | 103680-71-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ethyl 3-amino-2-phenylpropyl(diethoxymethyl)phosphinate
• 英文别名: 3-[diethoxymethyl(ethoxy)phosphoryl]-2-phenylpropan-1-amine
• CAS: 103680-71-3
• 化学式: C₁₆H₂₈NO₄P
• 分子量: 329.376
• InChiKey: JAVYNBKHSVNJPA-UHFFFAOYSA-N

物化性质

• 沸点：
  418.9±55.0 °C(Predicted)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-2-phenylpropyl(diethoxymethyl)phosphinate 在 盐酸 、 methyloxirane 作用下， 生成 3-氨基-2-苯基丙基亚膦酸
  参考文献：
  名称：

  Diethoxymethylphosphonites and phosphinates. Intermediates for thesynthesis of α,β- and X aminoalkylphosphonous acids

  摘要：

  DOI：

  10.1016/s0040-4020(01)89240-1
• 作为产物：
  描述：

  ethyl 3-nitro-2-phenylpropyl(diethoxymethyl)phosphinate 在 镍 氢气 作用下， 以 乙醇 为溶剂， 生成 ethyl 3-amino-2-phenylpropyl(diethoxymethyl)phosphinate
  参考文献：
  名称：

  Dingwall, J. G.; Ehrenfreund, J.; Hall, R. G., Phosphorus and Sulfur and the Related Elements, 1987, vol. 30, p. 571 - 574

  摘要：

  DOI：

文献信息

• Substituted propane-phosphonous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04656298A1

  公开（公告）日：1987-04-07

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  公式##STR1##中的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基（可选择地被卤素取代）、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，苯基部分可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个是氢，或其盐。这些化合物具有宝贵的药用性能。
• Substituted propane-phosponous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05457095A1

  公开（公告）日：1995-10-10

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为 ##STR1## 的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基，该苯基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，或C.sub.7-10-苯基烷基，该苯基烷基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个为氢，或其盐。这些化合物具有有价值的药物性质。
• Substituted propane-phosphonuous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04772738A1

  公开（公告）日：1988-09-20

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为##STR1##的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢，C.sub.1-8-烷基，C.sub.3-6-环烷基，苯基，该苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，该苯基烷基中的苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，而另外两个是氢，或其盐。这些化合物具有有价值的药物特性。
• N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
  申请人：Doherty A. George

  公开号：US20050020837A1

  公开（公告）日：2005-01-27

  The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖公式（I）的化合物以及其药学上可接受的盐和水合物。该化合物可用于治疗免疫介导的疾病和病况，如骨髓、器官和组织移植排斥反应。包括药物组合物和使用方法。
• Selective S1P1/Edg1 receptor agonists
  申请人：——

  公开号：US20040058894A1

  公开（公告）日：2004-03-25

  The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P 1 /Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR 3 /Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions and methods of use are included.

  本发明涵盖了一种治疗哺乳动物患者免疫调节异常的方法，包括向所述患者施用一种化合物，该化合物是S1P1/Edg1受体的激动剂，其剂量足以治疗所述免疫调节异常，其中所述化合物对S1P1/Edg1受体具有选择性，而非S1PR3/Edg3受体，所述化合物的剂量足以治疗所述免疫调节异常。药物组合物和使用方法也包括在内。